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OBJECTIVES: To examine and compare costs and cost drivers for various meta-
static renal cell carcinoma (mRCC) drugs. METHODS: This retrospective cohort 
study used administrative healthcare claims from MarketScan® Commercial 
and Medicare Supplemental Databases to identify patients newly diagnosed 
with mRCC (index event) from 1/1/2006 to 3/31/2014, with continuous health 
plan enrollment at least 6 months prior to and 30 days following the index 
date. Treatment with approved mRCC products on or after the index date was 
required. Patients were followed until death, health plan enrollment end, ini-
tiation of non-mRCC chemotherapy, or study end. Healthcare costs reflect paid 
amounts to providers and out-of-pocket costs to patients. Bootstrapping was used 
to determine differences between costs of drugs. RESULTS: The study population 
included 3060 mRCC patients. Total per-patient-per-month costs for pazopanib 
($14,486) and sorafenib ($13,841) were not statistically lower at an alpha level of 
0.05 than sunitinib ($15,808). However, temsirolimus ($19,431) and IL-2 ($96,619) 
were significantly more costly than sunitinib. For inpatient and patient out-of-
pocket costs, IL-2 was significantly more costly than sunitinib. Outpatient costs 
of pazopanib and temsirolimus were both significantly more costly than suni-
tinib while sorafenib was significantly less costly. Multivariate modeling found 
that year of index date, number of metastatic sites, NCI comorbidity index score, 
and evidence of an adverse event during first line treatment were significantly 
associated with greater costs for all patients. In general, approximately 46% of 
total costs were specific to mRCC drug costs while 30% were due to inpatient 
stay. CONCLUSIONS: This study demonstrates that there may be significant cost 
differences between mRCC drugs and that mRCC drug costs represent the largest 
driver of total healthcare costs in this patient population. Further research on 
comparative effectiveness, weighing costs relative to clinical benefit, is needed.
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OBJECTIVES: Colorectal cancer (CRC) is a major cause of morbidity and mortality 
worldwide. Approximately 25% of patients present metastatic disease at diagnosis 
and about 50% will develop metastatic disease. Patients with metastatic colorectal 
cancer (mCRC) and wild-type or mutated KRAS are eligible for sequential treat-
ments, including monoclonal antibodies as first or second-line regimens. Use of 
bevacizumab (Bev) through multiple lines (TML) may benefit patients with mCRC. 
Considering the emerging data, it is important to understand these implications 
in terms of costs for the Brazilian private healthcare system. Our objectives were 
to compare economic outcomes of different sequences of therapy including 
monoclonal antibodies for the treatment of mCRC. METHODS: Eight scenarios 
were analyzed, each one comparing different treatment sequences. A sequence 
of bevacizumab TML (first-line and beyond first progression) was compared in 
each scenario with another sequence without bevacizumab TML. To compare 
the economic outcomes, the monthly cost and the total cost of the sequence per 
patient were calculated, according to the first, second and third-lines combina-
tions. RESULTS: Considering a standard time of treatment of 12.8 months and 
progression-free survival (PFS) varying from 17.0 to 20.6, all scenarios with bevaci-
zumab TML were less costly than multiple lines without bevacizumab. The lowest 
monthly cost was related to bevacizumab TML (1stline bevacizumab 5mg+FOLFOX 
→ 2ndline bevacizumab 5mg+FOLFIRI → 3rdline best supportive care [BSC]). This 
sequence represents a monthly cost of R$ 18,192.41 per patient while the same 
scenario with cetuximab in first-line (1stline cetuximab 250mg+FOLFIRI → 2ndline 
bevacizumab 10mg+FOLFOX → 3rdline BSC) represents R$ 23,640.57 per month/
patient. CONCLUSIONS: Use of bevacizumab TML for mCRC is less costly compared 
with sequences of biological therapy that starts with cetuximab in the first-line fol-
lowed by bevacizumab in second-line treatment. Resource savings with sequential 
bevacizumab have the potential to optimize third-line treatment strategy for mCRC 
patients with wild-type KRAS in Brazil.
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OBJECTIVES: To investigate patterns of hemostat methods in surgeries and 
evaluate the healthcare resource utilization and economic burden of patients in 
China. METHODS: All Patients using oxidized regenerated cellulose (ORC), microfi-
brillar collagen hemostat (MCH), resorbable oxidized cellulose (ROC), and micropo-
rous polysaccharide hemispheres (MPH) after cholecystectomy, hysterectomy or 
other related surgeries in tertiary hospitals were identified from the 2012 dataset 
of the China Health Insurance Research Association (CHIRA) claims database which 
includes a nationwide, cross-sectional sampling of inpatients. Direct medical costs 
included diagnostic tests, surgery, physiotherapy, hemostat, medicines and consum-
ables cost. Descriptive statistics were used to describe patient profiles, healthcare 
resource utilization and direct medical cost. Two-tailed tests were performed at 95% 
confidence. Multiple linear regression (MLR) was used to identify main parameters 
that may influence inpatient costs thus providing patient selection criteria for a 
relative unbiased comparison. RESULTS: A total of 788 patients with the following 
characteristics, age, gender, surgery types, hemostats types, Length of Stay (LOS), 
Hospital tier were identified. Factors significantly impacted inpatient cost were 
Length of Stay, type of hemostat (ORC vs. others), tier of Medical Institute (MLR, 
p< 0.01). Among 382 patients who stayed at Tier 3 hospitals with LOS ≤ 14 days, the 
average inpatient costs of patients using ORC vs. other hemostats (MCH, ROC, MPH) 
were 21,101 RMB (±21,390), 23,246 RMB (±15,545), respectively. There was a signifi-
chronic pulmonary disease. The sunitinib cohort had less time between diagnosis and 
index prescription than the pazopanib cohort (334 vs. 422 days; p= 0.037). Proportions 
of patients with treatment continuation, discontinuation, switching, or interruption 
were NS different. Before imputation, adjusted mean [SD] daily medication costs dur-
ing persistence were higher for sunitinib ($218.19 [34.73] vs. $177.07 [45.76]; p< 0.0001), 
but NS different after imputation (sunitinib $181.41 [22.34] vs. pazopanib $175.77 
[44.26]; p= 0.213). Twelve-month adjusted RCC-related medical costs were signifi-
cantly lower for sunitinib than pazopanib before imputation ($36,638.96 [$25,199.38] 
vs. $45,219.75 [$34,828.70], p= 0.021) and after imputation ($36.393.90 [$26,543.89] vs. 
$45,652.99 [$35,226.83], p= 0.015. The RCC-related prescription costs were NS different 
between the two drugs before and after imputation. CONCLUSIONS: Treatment pat-
terns and persistence with sunitinib or pazopanib were NS different. Sunitinib daily 
cost was NS different from pazopanib after imputation. Further analysis is needed 
regarding dosing schedule, days supply, and related calculations.
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OBJECTIVES: The study aimed to (1) develop a cost model for colonoscopy prepa-
ration among patients referred for colonoscopy using split-dose reduced-volume 
oral sulfate solution (OSS) and generic polyethylene glycol with electrolytes solu-
tion (PEG-ELS), (2) examine cost-savings associated with OSS versus PEG-ELS, 
and (3) assess the robustness of the cost model. METHODS: Clinical efficacy of 
each agent was based on the results of a 541-patient clinical trial comparing OSS 
to PEG-ELS. Cleansing agent and colonoscopy procedure costs were calculated 
from OptumHealth Reporting & Insights claims data for 2010–Q12013. In the cost 
model, patients’ colonoscopies were tracked until the patient reached age 75. The 
difference per patient per year (PPPY) in total cleansing agent and colonoscopy 
procedure costs over the time horizon between the OSS and PEG-ELS cohort was 
calculated. One-way sensitivity analyses were also conducted to test the robust-
ness of the cost model. RESULTS: The cost model showed that OSS patients had 
fewer colonoscopies over the time horizon (OSS: 0.158 vs. PEG-ELS: 0.170 PPPY). 
Total PPPY costs were $280.34 for the OSS cohort and $296.36 for the PEG-ELS 
cohort, resulting in a cost-saving of $16.01 to the payer for the OSS cohort. Varying 
the annual colonoscopy completion rate, surveillance intervals, time horizon, and 
proportion of high risk patients did not change the observation of cost-savings 
under OSS. Cost-savings switched from the OSS to the PEG-ELS cohort in three 
cases: (1) base-case cost of a completed colonoscopy decreased by 75%, (2) base-
case cost of OSS increased to over $143 per usage, and (3) all non-completers 
were lost to follow up. CONCLUSIONS: From a payer’s perspective, the cost model 
showed that the use of OSS as the cleansing agent resulted in potential cost-
savings compared with PEG-ELS. The cost model was robust and cost-savings 
under OSS remained under various sensitivity analyses.
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OBJECTIVES: Cancer-related morbidity and mortality have dramatic impacts on 
patients and society. Most studies on the economic burden of cancer have focused 
on the direct costs attributed to healthcare expenditures or the indirect costs due 
to premature mortality. Cancer’s impact on absenteeism has been less well studied. 
The objective of this review was to summarize and characterize the literature on the 
economic impact of cancer-related absenteeism. METHODS: We searched PubMed for 
articles related to the costs of cancer-related absenteeism, which we defined as any 
type of workplace absence. Additional eligibility criteria included the evaluation of 
costs per patient and the presentation of absenteeism endpoints in monetary terms. 
Studies were characterized according to cancer type, healthcare setting (U.S., EU, Asia), 
valuation approaches, study time period, absenteeism endpoints, and cost results. 
All costs were adjusted to 2013 dollars or Euros using consumer price indexes and 
exchange rate data. RESULTS: We found 16 articles that met our inclusion criteria. 
Seven cancer or pre-cancer types were studied, with breast cancer (7 studies) and 
colorectal cancer (3 studies) being the most common. Absenteeism endpoints used 
by study authors varied considerably and included terms such as “absenteeism” (the 
actual term), “sick leave,” “short-term disability,” and “permanent disability (reduced 
hours or workforce departure).” For U.S. studies, total annual absenteeism costs per 
patient ranged from $3,235 (precancerous cervical lesions) to $59,241 (colorectal 
cancer). For European studies, total mean absenteeism costs per patient based on 
time until retirement age of 65 ranged from € 54,216 (breast cancer) to € 129,977 (colo-
rectal cancer). Overall, colorectal cancer was associated with the highest absentee-
ism costs. CONCLUSIONS: Based on the literature, it is apparent that cancer-related 
absenteeism poses a significant economic burden to patients, employers, and society. 
Additional research is required to better understand the absenteeism costs of various 
types of cancer and to make more accurate comparisons between them.
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the population was female (56.0%) with a mean Charlson comorbidity score of 0.43. 
Mean age was 21.6 years with 55.7% under the age of 18. The most common OP pro-
cedures were diagnostic (10.3%) while valve and septa operations (15.6%) and heart 
catheterization (11.9%) were the most frequent IP procedures. Mean LOS was 10.4 
days. Congestive heart failure (CHF) (RR 1.31, 95% CI 1.12, 1.51) fluid and electrolyte 
disorders (ED) (RR 1.68 CI1.46, 5.74), and ventricular septal defects (RR 1.33, CI1.09, 
1.62) diagnoses were associated with longer IP stays. 5.0% of patients admitted 
expired in the hospital and 8.5% were readmitted within 30 days. CHF (OR 2.26 CI 
1.10, 5.12), ED (OR 3.51 CI 1.49, 8.62), and cardiac dysrhythmias (OR 2.63 CI 1.22, 8.62), 
were associated with increased mortality. Only CHF (OR 2.64 CI 1.46, 4.68) was associ-
ated with increased readmissions. CONCLUSIONS: While EA patients are typically 
treated in the OP setting hospital utilization is high when IP services are required.
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OBJECTIVES: Thyroid cancer (TC) constitutes ~1% of all diagnosed cancers. DTC is 
the most common type of TC, accounting for about 95% of all cases. Most patients 
with DTC respond well to surgery and/or radioiodine therapy (I-131). However, 
< 5% of patients become refractory to I-131. Disease burden and healthcare costs 
associated with this orphan disease have not been well described. METHODS: This 
retrospective cohort analysis combined data from the Humana and OptumInsight 
Claims databases from Apr2005-Jun2014. Patients age > = 18 years were defined as 
having RAI-R DTC if they received a tyrosine-kinase inhibitor (TKI) and had > = 2 
diagnoses of thyroid cancer (ICD-9 code 193.xx) on or prior to the index date (first 
TKI use). Patients were excluded if no continuous medical/pharmacy coverage in 
the 6-months pre and post-index. Descriptive results included mean all-cause and 
thyroid-related total healthcare cost & utilization (inpatient, outpatient and phar-
macy), and were assessed 6 months post-index then converted to annual estimates. 
Results were reported for both the individual and combined datasets. RESULTS: A 
total of 116 patients ( Humana= 36; Optum= 80 patients) were identified. Mean age 
was 60 years and 45.7% were female. The average time from diagnosis to TKI use 
was 754 days. The most common TKIs were sorafenib (41.4%), sunitinib (26.7%), 
and vandetanib (14.7%), and 31.9% of patients used > = 2 TKIs. The average number 
of outpatient and ER visits were 43.4 and 1.2 for all-cause, and 22.2 and 0.3 for 
thyroid-related, respectively. Rates of hospitalization were 25.0% and 11.2% for all- 
and thyroid-related causes, with a mean stay of 7.8 and 5.1days, respectively. The 
average number of all-cause and thyroid-related prescriptions were 40.9 and 15.7, 
respectively. Total all- and thyroid-related annual healthcare costs were $127,935 
and $97,344, respectively. CONCLUSIONS: RAI-R DTC is a rare disease, with high dis-
ease burden as shown through high rates of healthcare utilization and annual cost.
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OBJECTIVES: We evaluated the economic burden of treating skeletal-related events 
(SREs), including pathologic fractures (PF), spinal cord compression (SCC), radia-
tion to bone (RB) and bone surgery (BS), in prostate cancer (PC) patients with bone 
metastasis (BM). METHODS: PC patients with a BM diagnosis between 01/01/2005 
and 03/01/2012 were identified in the Truven Health Analytics databases. Propensity 
score was used to match BM patients with SREs to those without. A pseudo-SRE date 
was assigned to the control group that was parallel to the SRE date of the matched 
SRE patients. We compared the total and per member per month (PMPM) costs of 
patients between two groups for the 6-month post-SRE/ pseudo-SRE date. RESULTS: 
We identified 4,975 PC men with BM where 910 patients with SREs were 1:1 matched 
to the non-SRE patients. For those men with at least one SRE, 95.8% received RB; 
17.6% had PF; 12% received BS; and 10.4% had SCC. On average, the total 6-month 
costs of treating patients with SREs were $47,724, compared to $24,729 for the 
matched control cohort (p< 0.001). The mean PMPM cost for non-SRE patients was 
$4,122. The largest proportion of differences in costs between two groups incurred 
in the first month after the SRE-index date ($16,564 vs. $4,636, p< 0.001), and were 
mostly attributable to outpatient visits (65.7%, p< 0.001) and inpatient hospitaliza-
tion (29.1%, p< 0.001). CONCLUSIONS: For PC patients with BM, costs of treating 
those with SREs are significantly higher than comparable patients without SREs. 
Most of costs were incurred in the first month after the occurrence of SREs, but 
while costs decreased thereafter, they remained significantly higher for patients 
with SRE in subsequent months.
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OBJECTIVES: Pancreatic cancer is considered one of the toughest cancers to treat, 
with extremely poor prognosis. The objective of this research was to conduct a 
systematic review of epidemiology and the burden of pancreatic cancer. METHODS: 
A systematic literature search for epidemiology and the burden of disease studies 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key find-
ings. Extracted study data included pancreatic cancer incidence, complications, 
cant difference in inpatient costs (p< 0.01) between the 2 groups. CONCLUSIONS: 
The economic burden of patients using new bio-surgical hemostatic materials was 
considerable. While a number of factors affected inpatient costs, patients using ORC 
were associated with lower total inpatient expenditure.
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OBJECTIVES: The objective of this literature review was to explore the existing evi-
dences regarding cost-effectiveness of allogeneic hematopoietic stem cell transplan-
tation (AHSCT) in hematologic cancers (HCs). METHODS: A systematic literature 
review was performed using the PICO method: Population consisted of patients suf-
fering from HCs; Intervention and Comparators were AHSCT compared to different 
types of AHSCT or standard therapies and Outcomes were incremental cost-utility 
ratios (ICURs) and/or incremental cost-effectiveness ratios (ICERs). The literature 
search was performed with the NHS EED filters using electronic databases from 
1948 until August 2014. RESULTS: The literature review allowed retrieving 5,805 
studies of which 13 fulfilled the eligibility criteria. Three studies included economic 
analysis on acute myeloid leukemia (AML), two on acute lymphoid leukemia (ALL), 
five on acute leukemias, three on chronic myeloid leukemia (CML) and one on 
myelodysplastic syndromes. Nine were cost-effectiveness analyses and four were 
cost-utility analyses. Five studies used a Markov model. The largest proportion of the 
studies compared AHSCT to standard chemotherapy (SC) (n= 5), followed by imatinib 
(n= 2) and various other comparators (n= 6). The time horizon varied from 1 year to 
lifetime. All studies used a health care system perspective. In AML and ALL, ICERs 
ranged from dominant to (2014US)$154,597/LYG compared to SC. In Philadelphia-
positive (Ph+) CML, ICERs for imatinib ranged from dominant to (2014US)$127,013/
QALY compared to AHSCT. CONCLUSIONS: Most of analyzed studies suggest that 
AHSCT is cost-effective in AML and ALL compared to SC, but not in Ph+CML when 
compared to imatinib, despite a wide cost-effectiveness ratios range. This is con-
sistent with current clinical practice in Ph+CML, where tyrosine kinase inhibitors, 
like imatinib, have replaced AHSCT for first-line therapy. Despite the high level of 
heterogeneity among selected studies, this review provides a comprehensive over-
view of the cost-effectiveness of AHSCT in HCs and could serve in the realization 
of future economic evaluations.
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OBJECTIVES: A literature search revealed no prior study on the direct medical 
costs for gynecologic cancer, including uterine, cervical, ovarian and other gyneco-
logic cancers. The study objective was to estimate the direct healthcare costs of 
gynecologic cancers among community-dwelling U.S. residents from an all-payer 
perspective. METHODS: A retrospective cross-sectional analysis was conducted 
using the 2007-2011 Medical Expenditure Panel Survey (MEPS) databases for patients 
with gynecologic cancers. Direct healthcare costs in the U.S. were estimated using 
gynecologic cancer-related expenditures by source of payment and service type. 
Generalized linear models with a gamma distribution and a log link were used 
to estimate adjusted mean expenditures based on patients’ characteristics. Costs 
were adjusted to 2011 U.S. dollars using the Consumer Price Index-Medical (CPI-
M). RESULTS: A total of 282 patients (average annual weighted N= 568,245) were 
identified with gynecologic cancer diagnoses across the study years. The estimated 
annual direct healthcare cost attributable to gynecologic cancers was $3.86 billion. 
The estimated average annual direct healthcare cost per patient was $6,794 (stand-
ard error [SE]= $1,269). Medicare accounted for most of the total expenditures (44%), 
followed by private insurance (38%). Over half (56%) of the total costs were generated 
by inpatient hospitalizations. The annual predicted costs (SE) per patient were $5,887 
($1,059) in patients with one type of gynecologic cancer and $13,129 ($6,573) in 
patients with two different types of gynecologic cancers. The annual predicted cost 
(SE) per patient with ovarian cancer was $15,693 ($7,912), which was higher than that 
for uterine ($9,590±$3,636) and cervical cancers ($7,935±$3,668). CONCLUSIONS: 
Gynecologic cancers place a considerable economic burden on society. The major-
ity of expenditures was driven inpatient hospitalizations and Medicare accounted 
for the largest portion of payments. This study can provide better understanding 
of the economic burden of gynecologic cancers and contribute to future policy on 
gynecologic cancer prevention and control programs.
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OBJECTIVES: Ebstein’s anomaly (EA) is a rare congenital heart disorder affecting the 
tricuspid valve in approximately one out of every 200,000 live births. Treatment for 
EA is focused on reducing symptoms and avoiding disease progression to complica-
tions like heart failure or arrhythmia. The objective of this analysis is to examine 
hospital-based utilization in patients with EA. METHODS: A retrospective cross-
sectional study was conducted on EA discharges in the MedAssets health system 
data for inpatient (IP) and outpatient (OP) visits between January 2009 and December 
2014. Age and gender, hospital characteristics, clinical comorbidities and meas-
ures of utilization including length of stay (LOS) and readmissions were described. 
Multivariable regression was used to identify significant drivers of hospital-based 
utilization. RESULTS: Hospital utilization occurred primarily in the OP setting 
(81.0%) in teaching facilities (88.3%) with 300 or more beds (78.1%). More than half 
